HeartFlow, Inc. (HTFL)
| Market Cap | 4.58B +60.0% |
| Revenue (ttm) | 238.66M +47.4% |
| Net Income | -79.02M |
| EPS | -0.92 |
| Shares Out | 87.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 810,565 |
| Open | 58.51 |
| Previous Close | 59.92 |
| Day's Range | 51.95 - 58.51 |
| 52-Week Range | 20.13 - 60.66 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 52.00 (-0.12%) |
| Earnings Date | Nov 12, 2026 |
About HTFL
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient’s heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart’s arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heart... [Read more]
Financial Performance
In 2025, HeartFlow's revenue was $176.03 million, an increase of 39.92% compared to the previous year's $125.81 million. Losses were -$116.79 million, 21.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for HTFL stock is "Strong Buy." The 12-month stock price target is $52.0, which is a decrease of -0.12% from the latest price.
News
Heartflow price target raised to $69 from $56 at Canaccord
Canaccord analyst William Plovanic raised the firm’s price target on Heartflow (HTFL) to $69 from $56 and keeps a Buy rating on the shares. The firm said Heartflow posted a…
Heartflow price target raised to $68 from $56 at Baird
Baird analyst David Rescott raised the firm’s price target on Heartflow (HTFL) to $68 from $56 and keeps an Outperform rating on the shares. The firm updated its model following…
Heartflow price target raised to $70 from $45 at Stifel
Stifel analyst Rick Wise raised the firm’s price target on Heartflow (HTFL) to $70 from $45 and keeps a Buy rating on the shares.
Heartflow price target raised to $70 from $39 at Wells Fargo
Wells Fargo raised the firm’s price target on Heartflow (HTFL) to $70 from $39 and keeps an Overweight rating on the shares. The firm cites a strong Q3 beat and…
HeartFlow Earnings Call Transcript: Q3 2026
Q3 revenue grew 57.4% YoY, with strength in FFRct and Plaque Analysis prompting higher FY26 revenue and margin guidance. Clinical data and expanding CCTA adoption underpin longer-term growth, while cash flow profitability is targeted by mid-2028.
HeartFlow Earnings release: Q3 2026
HeartFlow released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
HeartFlow Quarterly report: Q3 2026
HeartFlow has published its Q3 2026 quarterly earnings report on November 12, 2026.
Heartflow reports Q3 adjusted EPS (3c), consensus (10c)
Reports Q3 revenue $72.86M, consensus $65.2M. “Our third quarter was excellent, with revenue accelerating for the third consecutive quarter and U.S. revenue growing at its fastest pace in 11 quarters,...
Heartflow raises FY26 revenue view to $262M-$264M from $246M-$250M
Consensus $248.63M. Raises FY26 gross margin view to 82.5% from 82%.
Heartflow Reports Third Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today reported finan...
AHA 2026: Heartflow Plaque Analysis Associated with 34% Fewer Major CVD Events and Half the Rate of Heart Attack at One Year in Prospective DECIDE Registry
First plaque tool with prospective outcomes data. Faster, sustained LDL-C control: approximately 50% of patients reached goal by 90 days vs.
Heartflow announces P4 study of CT-guided PCI planning met primary endpoint
Heartflow (HTFL) announced new randomized clinical data presented at Transcatheter Cardiovascular Therapeutics, TCT, the annual scientific symposium of the Cardiovascular Research Foundation, demonstr...
TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients
Late-Breaking P4 study, simultaneously published in NEJM, shows CT guidance delivers matched one-year clinical outcomes with shorter procedures, demonstrating pre-procedural CCTA can guide key PCI pla...
Boston Scientific announces results for third quarter 2026
MARLBOROUGH, Mass., Oct. 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.138 billion during the third quarter of 2026, growing 1.5 percent on a reported, o...
Heartflow price target raised to $64 from $45 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on Heartflow (HTFL) to $64 from $45 and keeps an Overweight rating on the shares. After analyzing the company’s technology…
Heartflow to Report Third Quarter 2026 Financial Results on November 12, 2026
SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced it w...
Heartflow price target raised to $56 from $45 at Canaccord
Canaccord analyst William Plovanic raised the firm’s price target on Heartflow (HTFL) to $56 from $45 and keeps a Buy rating on the shares. HeartFlow appears to maintain a strong…
HeartFlow Transcript: Wells Fargo 21st Annual Healthcare Conference
AI-driven coronary artery disease diagnostics are accelerating growth, with Plaque Analysis adoption and revenue surging, supported by robust clinical data and expanding payer coverage. Strategic RCTs target a $6B asymptomatic market, aiming for $11B TAM by 2030 and profitability by mid-2028.
Heartflow initiated with a Neutral at UBS
UBS initiated coverage of Heartflow (HTFL) with a Neutral rating and $55 price target The firm initiated and resumed 25 life science and diagnostics tools companies. UBS views life science…
Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half
FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, suppo...
Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference
SAN FRANCISCO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced that...
Heartflow price target raised to $40 from $35 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh raised the firm’s price target on Heartflow (HTFL) to $40 from $35 and keeps an Equal Weight rating on the shares.
Heartflow reports Q2 EPS (7c), consensus (13c)
Reports Q2 revenue $64.1M, consensus $56.64M. “The second quarter reflects the growing strength of Heartflow’s (HTFL) category leadership and unique AI technology platform for identifying, diagnosing,...
Heartflow increases FY26 revenue view to $246M-$250M from $228M-$232M
Consensus $230.08M
Heartflow price target raised to $45 from $34 at Baird
Baird raised the firm’s price target on Heartflow (HTFL) to $45 from $34 and keeps a Neutral rating on the shares. The firm updated its model following blowout beat and…